Vivor helps patients receive financial assistance by focusing on empowering the providers and making it easier for financial navigators to do their job, said Ian Manners, founder and CEO of Vivor.
Vivor helps patients receive financial assistance by focusing on empowering the providers and making it easier for financial navigators to do their job, said Ian Manners, founder and CEO of Vivor.
Transcript
How is VIvor helping patients receive financial assistance?
We really focus on empowering providers. So, we find that our tools are most effective when they’re paired up with a great financial navigator or financial advocate who works right there in the private practice or in the hospital. That’s someone who can meet with the patient in person, really make sure that they’re intervening early on in a treatment process or even before treatment is begun.
We really make it easier for the financial advocate or navigator to do his or her job better. We give them the tools so they know exactly what kinds of answers to provide for their patient. We give them print outs that they can share with patients with information about financial resources, pin codes that the patient can then go enter on a mobile device or a laptop at home once they’ve had a chance to digest everything and talk it over with family members and caregivers.
Really, it’s all about empowering that person who is at the bedside, to do a better job of working with the patient.
What are the most common disease states you see among patients Vivor is working with?
We cover the gamut. We cover all specialty drugs, all disease areas that are made available through nonprofit foundations nationally. We track around 700 different sources of assistance. But oncology happens to be where the need is most focused, most acute. Around half of the resources that we track are in oncology, and I would say that the majority of the programs that we’re working with on the provider side are cancer centers.
That said, they tend to work with a large range of patient populations, just because when they’re operating in an infusion center, most likely they’re going to be treating patients with rheumatoid arthritis, with multiple sclerosis, many other indications where there are infused medicines.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
2 Commerce Drive
Cranbury, NJ 08512